NEW YORK – Todos Medical announced on Monday a development and commercialization partnership with Singapore-based Pathnova for Todos' breast cancer and SARS-CoV-2 diagnostic kits.
Pathnova, a spinout of Temasek Life Sciences Laboratory, will further develop and commercialize Todos' tests in Singapore, while Todos will assist Pathnova to commercialize its nasopharyngeal cancer tests through its affiliates in the US and Singapore.
Todos said it will provide Pathnova access to existing clinical datasets for its breast cancer diagnostics TM-B1 and TM-B2. The partners will work to optimize Todos' AI-driven algorithm to support regulatory approval in the US and Singapore. Additionally, Pathnova will support Todos to distribute its tests in Singapore and Southeast Asia in collaboration with Todos Medical Singapore, a wholly owned subsidiary of Rehovot, Israel-based Todos.
Financial terms of the deal were not disclosed.
Pathnova is focused on developing technologies for detecting nasopharyngeal cancer and autoimmune diseases.